Hearing Stability Following IGF‐1R Inhibitor Treatment in Mice

Christopher Ward, David Redhage, Caridad Naanep, Mateo Salazar, Osama Tarabichi, Bryce Hunger, Md Fahad Hossain, Adam Vaske, Aditya Alluri, Kamelia Zerrouki, Giustino Carnevale, Mohamed Amine Lounis, Brajesh Kumar, Marlan R. Hansen, Chang‐Rung Chen, Alexander D. Claussen
Laryngoscope · Wiley · 2026-11-16 · DOI: 10.1002/lary.71063

Аннотация

ABSTRACT Objectives Teprotumumab is a novel monoclonal antibody treatment for thyroid eye disease that acts through IGF‐1R inhibition. A subset of patients has been reported to experience varying levels of hearing change and other otologic symptoms after therapy. This study aimed to investigate auditory changes following monoclonal antibody IGF‐1R inhibitor treatment in mice. Methods Adult CBA/CaJ mice were treated with varying doses of a chimeric IGF‐1R monoclonal antibody (cIGF‐1R mAb), saline, or IgG2a isotype controls ( n = 10 per group) weekly for 20 weeks. Mice underwent auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) testing at regular intervals. Suprathreshold ABR Wave 1 amplitude growth functions were analyzed at the final timepoint, along with histological assessment of auditory hair cells and presynaptic ribbons. Bodyweight, exposure of cIGF‐1R mAb, and the inhibitory effect of cIGF‐1R mAb in lung tissues were also assessed. Results At 20 weeks, there was no significant increase in ABR or DPOAE threshold shift of the experimental cIGF‐1R mAb groups compared with saline controls. No significant decrease in hair cell and presynaptic ribbon counts or suprathreshold ABR Wave 1 amplitude growth functions were observed amongst cIGF‐1R mAb‐treated subjects compared with saline controls. Inhibitory activity of cIGF‐1R mAb was confirmed by the reduced bodyweight gain compared with controls and sustained IGF‐1R pathway inhibition over the study period. Conclusion IGF‐1R inhibition in mice shows no consistent electrophysiologic or histological effect on auditory function. Further animal and clinical studies are warranted to evaluate a potential association between IGF‐1R treatment and hearing loss. Level of Evidence N/A

Читать у издателя →

Похожие статьи